Anti-CD8 (Human) LIMAAbody® #10003

Documentation:

• Download Datasheet

• Download MSDS

Product Information:

Applications tested
Immunofluorescence staining, wholemount tissue staining.

Specificity/Target
Human CD8. Validated on human tissue samples and human PBMCs. 

Type
Nanobody, single-domain antibody, VHH

Clone
3ALB177

Reactivity
Human. Reactivity based on IF and IHC stainings of tissue samples and IF staining of PBMCs.

Immunogen
Recombinant protein containing the extracellular domain of human CD8 protein.

Class
Recombinant, produced in E.coli.

Host
Alpaca

Sensitivity
Endogenous protein expression.

Conjugate
Unconjugated.
Suitable for conjugation of fluorescent dyes, biotin, beads, surfaces etc. via NHS ester chemistry.

VHH protein tag
C-terminal (6x)His-Tag

Purity
Affinity-purified antibody fragment.

Molecular Weight
13 kDa

Form
Buffered solution.

Storage buffer
Phosphate buffered saline (PBS), pH=7,4; Preservative: 0.03% Sodium azide.

Storage condition
Shipped at ambient temperature. Upon receipt store at 4°C. Stable for 6 months. Do not freeze.

Product Usage Information
For optimal immunofluorescence staining results, use nanobody at concentrations between 10-30µg/ml in combination with recommended LIMAA reagents and protocols.

Application and Dilution
Immunofluorescence (frozen sections): 10 µg/ml
Immunofluorescence (cell culture): 10 µg/ml
lmmunofluorescence (wholemount tissue staining): 20 µg/ml
Flow Cytometry (FACS): 10 µg/ml

Background
CD8, also known as cluster of differentiation 8, is a cell surface glycoprotein expressed primarily on cytotoxic T cells, but also on natural killer cells and some dendritic cells. As a critical component of the immune system, CD8 serves as a co-receptor for the T cell receptor (TCR) and plays an essential role in antigen recognition and T cell activation. Upon binding to major histocompatibility complex (MHC) class I molecules presenting antigens derived from intracellular pathogens or aberrant cells, CD8 facilitates the initiation of the immune response, leading to the destruction of infected or malignant cells through the release of cytotoxic molecules and the induction of apoptosis. The dynamic regulation of CD8 expression and function is essential for orchestrating effective immune responses against pathogens and tumors, making it a key molecule for research aimed at understanding and manipulating immune-mediated diseases.

Trademarks and Patents
LIMAAbody® is a trademark of LIMAA Technologies GmbH.
ATTO is a registered trademark of ATTO-TEC GmbH.
All other trademarks are the property of their respective owners.

Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of LIMAA, the following terms apply to Products provided by LIMAA, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of LIMAA, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA, EMA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by LIMAA are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from LIMAA. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with LIMAA products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with LIMAAs terms of sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.